XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells

202525 citationsJournal Articlehybrid Open Access

Authors

These data provide a robust preclinical characterization of XMT-2056 and provide rationale and strategy for its clinical evaluation.

Good health and well-being

Published in: Clinical Cancer Research

Volume 31, Issue 9, pp. 1766-1782

Field-Weighted Citation Impact: 19.74